Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Long-Term Debt Repayments (2024 - 2025)

Tonix Pharmaceuticals Holding has reported Long-Term Debt Repayments over the past 2 years, most recently at $50000.0 for Q2 2025.

  • Quarterly results put Long-Term Debt Repayments at $50000.0 for Q2 2025, down 92.91% from a year ago — trailing twelve months through Dec 2025 was $9.6 million (up 310.64% YoY), and the annual figure for FY2025 was $9.6 million, up 310.64%.
  • Long-Term Debt Repayments for Q2 2025 was $50000.0 at Tonix Pharmaceuticals Holding, down from $9.6 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for TNXP hit a ceiling of $9.6 million in Q1 2025 and a floor of $50000.0 in Q2 2025.